Commercial bribery has become a "stumbling block" for pharmaceutical enterprises. Has shenghuaxi pharmaceutical industry been launched

Securities Daily reported on May 2 that the issuance and review meeting held on that day reviewed the IPO applications of 7 companies, among which 6 companies including Zheshang Securities Co., Ltd were approved and Chongqing shenghuaxi Pharmaceutical Co., Ltd was not approved As a result, 19 companies have not applied for IPO this year Source: China Youth Network It is worth noting that in the review process of Chongqing shenghuaxi Pharmaceutical Co., Ltd., the issue of commercial bribery was once again mentioned by the Audit Committee: the specific component of the promotion fee and academic promotion fee in each period of the report period, whether the relevant doctors, medical personnel, medical representatives or customers have been given kickbacks, off account rebates, gifts in the promotion and academic promotion activities, whether there is any commitment The said personnel or their relatives' domestic and foreign tourism expenses and other disguised commercial bribery   At the same time, the IEC proposed the reasons, contract basis and compliance for the traditional regional distribution mode to remit the sales incentive fee to the dealer's authorized representative account (personal account), whether the personal account is under the control of the dealer unit or under the control and use of the individual, the provider and specific content of the reimbursement bill during the declaration period, whether the bill content is consistent with the sales incentive fee, and whether the reimbursement bill is consistent with the sales incentive fee It is true, legal and compliant, whether there is commercial bribery or providing convenience for commercial bribery, whether it complies with the tax law, anti unfair competition law, bank settlement system, financial system and other relevant provisions, and whether there is legal risk in the way of payment In addition, combined with the way and process of order acquisition, the implementation and effectiveness of the issuer's relevant financial and internal control system are supplemented to explain whether the issuer's relevant internal control system can effectively prevent the risk of commercial bribery In the case of Nanjing Shenghe Pharmaceutical Co., Ltd., which was rejected on March 27 this year, the IEC also raised the issue of commercial bribery: whether there were any kickbacks, off account rebates, gifts given to relevant doctors, medical personnel, medical representatives or customers in the marketing activities, whether there were disguised commercial bribery behaviors such as bearing the domestic and foreign travel expenses of the above-mentioned personnel or their relatives In addition, Haier Shi biomedical Co., Ltd., which originally planned to conduct an online roadshow on August 17 last year, announced on the same day that the issuer decided to suspend the follow-up issuance due to media queries It is reported that the suspension of the issue directly refers to the media exposure of the subsidiary Shanghai Haier Shi and its employees involved in a number of commercial bribery scandals.